Evidence map›Paper›PMID 32628905›Full record

ReviewThe Lancet. Infectious diseases2020

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.

Eskild Petersen, Marion Koopmans, Unyeong Go, Davidson H Hamer, Nicola Petrosillo, Francesco Castelli, Merete Storgaard, Sulien Al Khalili, Lone Simonsen

Abstract readReview
In one paragraph

Review in The Lancet. Infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 669 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
669citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

669 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Review
  11. Article
  12. Review
  13. Article
  14. Usambarensine fromACS omega · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

609 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Eskild PetersenEuropean Society for Clinical Microbiology and Infectious Diseases, Basel, Switzerland; Department of Molecular Medicine, The University of Pavia, Pavia, Italy; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Electronic address: eskild.petersen@gmail.com.
Marion KoopmansEuropean Society for Clinical Microbiology and Infectious Diseases, Basel, Switzerland; Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands.
Unyeong GoInternational Tuberculosis Research Center, Seoul, South Korea.
Davidson H HamerDepartment of Global Health, Boston University School of Public Health, Boston, MA, USA; Department of Medicine, Boston University School of Medicine, Boston, MA, USA; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Nicola PetrosilloEuropean Society for Clinical Microbiology and Infectious Diseases, Basel, Switzerland; Department of Clinical Research, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy.
Francesco CastelliDepartment of Infectious and Tropical Diseases, Spedali Civili and University of Brescia, Brescia, Italy.
Merete StorgaardEuropean Society for Clinical Microbiology and Infectious Diseases, Basel, Switzerland; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
Sulien Al KhaliliDirectorate General for Disease Surveillance and Control, Ministry of Health, Muscat, Oman.
Lone SimonsenDepartment of Science and Environment, Roskilde University, Roskilde, Denmark; Department of Global Health, George Washington University, Washington, DC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this Personal View is to compare transmissibility, hospitalisation, and mortality rates for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with those of other epidemic coronaviruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), and pandemic influenza viruses. The basic reproductive rate (R

Indexed as

PandemicsAge FactorsBetacoronavirusCoronavirus InfectionsCOVID-19EpidemicsHospitalizationHumansHygieneInfluenza, HumanPhysical DistancingPneumonia, ViralSARS-CoV-2Severe Acute Respiratory Syndrome

Identifiers

PMID32628905
PMCPMC7333991

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.